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Hypertension and impaired renal angiotensin II response in rats
after chronic neuronal nitric oxide synthase inhibition. Nitric
oxide (NO) produced by the macula densa cells is important for
the control of tubuloglomerular feedback (TGF). Reduced pro-
duction of NO by these cells activates TGF and could result in
hypertension, although the TGF activity is then normalized in the
hypertensive state. The normalization of TGF in this form of
hypertension might be explained by an impaired ability of angio-
tensin II to constrict renal vessels or by up-regulation of some
other vasodilator not affected by NO synthase inhibitors.
The nitric oxide (NO) system seems to play a major role
in the regulation of many renal mechanisms. Not only are
all of the known isoforms of NO synthase (NOS) expressed
in the kidney [1], but the finding that low doses of inhibitors
of NOS increase renal vascular resistance and reduce renal
blood flow (RBF) without changing systemic blood pres-
sure (BP) [2, 3] indicates that the renal vasculature may be
particularly sensitive to changes in NO synthesis. The
discrepancy between the effects of NO on renal and
peripheral vessels suggests also that there may be funda-
mental differences in how NO affects the tonus of renal
vessels and those of other organs [4].
NITRIC OXIDE AND TUBULOGLOMERULAR
FEEDBACK
The important finding that macula densa (MD) cells
contain the neuronal isoform of NOS (nNOS) [5] directed
the interest of renal physiologists to new approaches.
Indeed, initial studies showed that NO from the MD might
be of significance for tubuloglomerular feedback (TGF)
[6]. Moreover, local intrarenal NOS blockade increases the
tone of the afferent but not the efferent arteriole [7], and
NO from the MD cells affects the tone of the afferent
arteriole only when the MD plaque is perfused with NaCl
at a high and not a low concentration, suggesting that NO
is important for TGF regulation [8]. Our laboratory has
confirmed these results. NOS inhibition (both systemic and
at the single nephron level) resets the sensitivity of the TGF
system [9, 10]. Selective inhibition of different isoforms of
NOS shows that nNOS in the MD cells is the most
important source of NO for counteracting the TGF-medi-
ated vasoconstriction [11]. Recent studies have strength-
ened and expanded the view that NO is one of the most
important factors in TGF regulation [12, 13], although it
does not seem to be involved in MD signaling [13]. NO is
merely a counteractive factor, balancing the TGF-mediated
constriction of afferent arterioles.
LONG-TERM INHIBITION OF NITRIC OXIDE
SYNTHESIS AND HYPERTENSION
Long-term treatment of most laboratory animals with
NOS blockers dose dependently elevates systemic arterial
BP [14]. This hypertension is associated with dramatic
changes in vascular resistance and in renal hemodynamics.
Similarly, chronic administration of an unspecific NOS
inhibitor for up to two months elevated BP and increased
renal vasoconstriction [15], and that chronic NOS inhibi-
tion is associated with increased glomerular capillary pres-
sure and increased resistance of both afferent and efferent
arterioles [16]. Hence, renal vasoconstriction as a result of
chronic NOS inhibition may play an important role in the
development of hypertension in this model.
Tubuloglomerular feedback sensitivity is increased dur-
ing the development of hypertension in some strains of
spontaneously hypertensive rats [17, 18]. The fact that NOS
inhibition increases TGF sensitivity and that this inhibition
seems to have less effect on TGF in hypertensive than in
normotensive animals [19] suggested that selective block-
ade of nNOS in MD cells with 7-nitroindazole (7-NI) [20]
might activate TGF and, through mechanisms similar to
those suggested for spontaneously hypertensive rats, might
elevate BP. Indeed, after a one-week treatment of normo-
tensive Sprague-Dawley rats with 7-NI, arterial BP (mea-
sured using a noninvasive tail-cuff technique) increased
from 134 6 3 mm Hg to 143 6 6 mm Hg and, after four
weeks, stabilized at 152 6 4 mm Hg [21]. However, neither
the TGF sensitivity nor the glomerular filtration rate
(GFR) differed from those in vehicle-treated normotensive
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rats. Experiments conducted after acute administration and
after the first week of nNOS inhibition showed that the
TGF system was strongly activated during this stage. GFR
was also decreased after the acute administration of 7-NI;
however, as TGF slowly normalized, GFR also returned to
normal, and the BP increased. Although systemic nNOS
inhibition might affect the BP through other mechanisms
involving the central nervous system and peripheral nerve
endings (both rich in nNOS), our results may indicate that
attenuated NO production in MD cells might be one
important factor for the development of hypertension.
Interestingly, intrarenal or, more specifically, medullary
interstitial infusion of 7-NI in conscious, normotensive rats
elevates BP dose dependently [22]. This indicates that 7-NI
affects the renal circulation even without any conceivable
influence on the nervous system.
IMPAIRED RENAL RESPONSE TO ANGIOTENSIN II
AFTER CHRONIC NEURONAL NITRIC OXIDE
SYNTHASE INHIBITION
In the hypertensive state, rats treated chronically with
7-NI have normal TGF responsiveness, as do adult spon-
taneously hypertensive rats [17, 18]. Whether this normal-
ization of TGF is the result of up-regulation of other
vasodilators (other NOS isoforms or unknown vasodila-
tors) or whether it is a consequence of reduced efficiency of
vasoconstrictors acting on the afferent arteriole is not
known. In our laboratory, recent experiments in which
intracellular Ca21 was measured in isolated renal afferent
arterioles from chronic 7-NI rats showed a reduced re-
sponse to angiotensin (Ang) II. The response to norepi-
nephrine (NE), however, was normal. We therefore tested
the vasoconstrictive response of the renal vasculature to
Ang II, which is important for TGF-mediated constrictions,
and to NE by measuring RBF (with an ultrasonic flow
probe on the renal artery) in chronically 7-NI—treated
anesthetized rats. RBF did not differ between control rats
and 7-NI—treated rats (5.15 6 0.75 and 4.32 6 0.9 ml/min,
respectively). The response to i.v. NE (40-ng bolus) was
similar between control and 7-NI—treated animals and was
used as a measure of the constrictive capacity of the
vasculature. The response of RBF to Ang II was signifi-
cantly stronger in controls than in 7-NI—treated rats (Ang
II reduced RBF to 67% of the NE response in controls but
only to 31% in 7-NI rats). Subsequent systemic administra-
tion of an unspecific NOS inhibitor (NLA, 10 mg/kg bolus
and 3 mg/kg continuously) increased the BP in both groups
(24% in controls and 16% in 7-NI rats), but the difference
in the response to Ang II between the two groups persisted.
These results indicate that long-term nNOS inhibition in
some way impairs the renal response to Ang II. The
up-regulation of some other isoform of NOS cannot ex-
plain this observation, as the difference between treated
and nontreated animals persists after nonspecific NOS
blockade.
APPENDIX
Abbreviations used in this article are: Ang II, angiotensin II; BP, blood
pressure; GFR, glomerular filtration rate; MD, macula densa; NE,
norepinephrine; 7-NI, 7-nitroindazole; nNOS, neuronal nitric oxide syn-
thase; NO, nitric oxide; NOS, nitric oxide synthase; RBF, renal blood flow;
TGF, tubuloglomerular feedback.
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